Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merit Medical Systems (MMSI) Gains from Sales and Divestitures (2016 - 2025)

Merit Medical Systems' Gains from Sales and Divestitures history spans 12 years, with the latest figure at $98000.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 390.0% year-over-year to $98000.0; the TTM value through Dec 2025 reached $98000.0, up 390.0%, while the annual FY2025 figure was $98000.0, 390.0% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $98000.0 at Merit Medical Systems, up from $20000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $98000.0 in Q4 2025 and bottomed at $20000.0 in Q4 2024.
  • The 5-year median for Gains from Sales and Divestitures is $31000.0 (2023), against an average of $43800.0.
  • The largest annual shift saw Gains from Sales and Divestitures plummeted 35.48% in 2024 before it surged 390.0% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $26000.0 in 2021, then soared by 69.23% to $44000.0 in 2022, then dropped by 29.55% to $31000.0 in 2023, then tumbled by 35.48% to $20000.0 in 2024, then soared by 390.0% to $98000.0 in 2025.
  • Per Business Quant, the three most recent readings for MMSI's Gains from Sales and Divestitures are $98000.0 (Q4 2025), $20000.0 (Q4 2024), and $31000.0 (Q4 2023).